| 1 |
Gialouri CG, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int 2023;43:421-35. [PMID: 36635577 DOI: 10.1007/s00296-022-05270-6] [Reference Citation Analysis]
|
| 2 |
Gilmore R, Tassone D, Ding NS. Letter: tofacitinib in the real world - do clinical trial data stand up? Aliment Pharmacol Ther 2023;57:745-6. [PMID: 36821748 DOI: 10.1111/apt.17402] [Reference Citation Analysis]
|
| 3 |
Straatmijer T, van Schaik FDM, Bodelier AGL, Visschedijk M, de Vries AC, Ponsioen CY, Pierik M, van Bodegraven AA, West RL, de Boer NKH, Srivastava N, Romkens TEH, Hoekstra J, Oldenburg B, Dijkstra G, van der Woude JC, Löwenberg M, Mujagic Z, Biemans VBC, van der Meulen-de Jong AE, Duijvestein M. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry. Aliment Pharmacol Ther 2023;57:117-26. [PMID: 36282200 DOI: 10.1111/apt.17248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Chaparro M, Acosta D, Rodríguez C, Mesonero F, Vicuña M, Acosta MB, Fernández-Clotet A, Martínez ÁH, Arroyo M, Vera I, Ruiz-Cerulla A, Sicilia B, Cabello Tapia MJ, Villafranca CM, Castro-Poceiro J, Cadilla JM, Sierra-Ausín M, Vázquez Morón JM, Lidón RV, Bermejo F, Royo V, Calafat M, González-Muñoza C, Carnerero EL, Marcos NM, Torrealba L, Alonso-Galán H, Benítez JM, Nieto YB, Diz-Lois Palomares MT, García MJ, Muñoz JF, Armesto González EM, Calvet X, Hernández-Camba A, Madrigal Domínguez RE, Menchén L, Pérez Calle JL, Piqueras M, Sadornil CD, Botella B, de Jesús Martínez-Pérez T, Ramos L, Rodríguez-Grau MC, San Miguel E, Fernández Forcelledo JL, Fradejas Salazar PM, García-Sepulcre M, Gutiérrez A, Llaó J, Abizanda ES, Boscá-Watts M, Iyo E, Keco-Huerga A, Bonil CM, González EP, Pérez-Galindo P, Varela P, Gisbert JP. Real-world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety. Am J Gastroenterol 2022. [PMID: 36716287 DOI: 10.14309/ajg.0000000000002145] [Reference Citation Analysis]
|
| 5 |
Taneja V, El-Dallal M, Haq Z, Tripathi K, Systrom HK, Wang LF, Said H, Bain PA, Zhou Y, Feuerstein JD. Effectiveness and Safety of Tofacitinib for Ulcerative Colitis: Systematic Review and Meta-analysis. J Clin Gastroenterol 2022;56:e323-33. [PMID: 34516458 DOI: 10.1097/MCG.0000000000001608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 6 |
Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Rev Gastroenterol Hepatol 2022;16:737-52. [PMID: 35875997 DOI: 10.1080/17474124.2022.2106216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Verstockt B, Volk V, Jaeckel C, Alsoud D, Sabino J, Nikolaus S, Outtier A, Krönke N, Feuerhake F, De Hertogh G, Rosenstiel P, Vermeire S, Schreiber S, Ferrante M, Aden K. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 2022;56:282-91. [PMID: 35484689 DOI: 10.1111/apt.16955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 8 |
Katsanos KH, Armuzzi A. Effectiveness and safety of tofacitinib in ulcerative colitis: Done is better than perfect. Dig Liver Dis 2022;54:151-3. [PMID: 34953762 DOI: 10.1016/j.dld.2021.11.017] [Reference Citation Analysis]
|
| 9 |
Avni-Biron I, Bar-Gil Shitrit A, Koslowsky B, Levartovsky A, Kopylov U, Weisshof R, Aviv Cohen N, Maharshak N, Hovel D, Israeli E, Naftali T, Goren I, Snir Y, Ollech JE, Banai-Eran H, Broitman Y, Sharar-Fischler T, Dotan I, Yanai H. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Dig Liver Dis 2022;54:192-7. [PMID: 34887214 DOI: 10.1016/j.dld.2021.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Lucaciu LA, Constantine-Cooke N, Plevris N, Siakavellas S, Derikx LAAP, Jones GR, Lees CW. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:17562848211064004. [PMID: 34987608 DOI: 10.1177/17562848211064004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 11 |
Kim JW, Kim SY. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. Int J Mol Sci 2021;22:11322. [PMID: 34768752 DOI: 10.3390/ijms222111322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Lucaciu L, Constantine-cooke N, Plevris N, Siakavellas S, Derikx L, Jones G, Lees C. Real-world experience with tofacitinib in ulcerative colitis - a systematic review and meta-analysis.. [DOI: 10.1101/2021.04.27.21256170] [Reference Citation Analysis]
|
